

Global Malignant Mesothelioma Drugs Market Growth 2024-2030

<https://marketpublishers.com/r/G44BC089151FEN.html>

Date: May 2024

Pages: 145

Price: US\$ 3,660.00 (Single User License)

ID: G44BC089151FEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

The global Malignant Mesothelioma Drugs market size is projected to grow from US\$ million in 2023 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Malignant Mesothelioma Drugs Industry Forecast” looks at past sales and reviews total world Malignant Mesothelioma Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Malignant Mesothelioma Drugs sales for 2024 through 2030. With Malignant Mesothelioma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Malignant Mesothelioma Drugs industry.

This Insight Report provides a comprehensive analysis of the global Malignant Mesothelioma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Malignant Mesothelioma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Malignant Mesothelioma Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Malignant Mesothelioma Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Malignant Mesothelioma Drugs.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report presents a comprehensive overview, market shares, and growth opportunities of Malignant Mesothelioma Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type

Pemetrexed

Cisplatin

Carboplatin

Gemcitabine

Vinorelbine

Others

Segmentation by application

Hospital Pharmacies

Retail Pharmacies

Oncology Centers

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Bristol-Myers Squibb

Roche

Merck

Novartis

Pfizer

Sanofi

Eli Lilly

Teva Pharmaceuticals

Boehringer Ingelheim GmbH

Mylan

Fresenius Kabi

Sun Pharmaceuticals

Corden Pharma

Concordia International

Kyowa Hakko Kirin

Polaris Pharmaceuticals

MolMed

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Malignant Mesothelioma Drugs market?

What factors are driving Malignant Mesothelioma Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Malignant Mesothelioma Drugs market opportunities vary by end market size?

How does Malignant Mesothelioma Drugs break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Malignant Mesothelioma Drugs Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Malignant Mesothelioma Drugs by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Malignant Mesothelioma Drugs by Country/Region, 2019, 2023 & 2030

2.2 Malignant Mesothelioma Drugs Segment by Type

- 2.2.1 Pemetrexed
- 2.2.2 Cisplatin
- 2.2.3 Carboplatin
- 2.2.4 Gemcitabine
- 2.2.5 Vinorelbine
- 2.2.6 Others

2.3 Malignant Mesothelioma Drugs Sales by Type

- 2.3.1 Global Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)
- 2.3.2 Global Malignant Mesothelioma Drugs Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Malignant Mesothelioma Drugs Sale Price by Type (2019-2024)

2.4 Malignant Mesothelioma Drugs Segment by Application

- 2.4.1 Hospital Pharmacies
- 2.4.2 Retail Pharmacies
- 2.4.3 Oncology Centers
- 2.4.4 Others

2.5 Malignant Mesothelioma Drugs Sales by Application

2.5.1 Global Malignant Mesothelioma Drugs Sale Market Share by Application (2019-2024)

2.5.2 Global Malignant Mesothelioma Drugs Revenue and Market Share by Application (2019-2024)

2.5.3 Global Malignant Mesothelioma Drugs Sale Price by Application (2019-2024)

3 GLOBAL MALIGNANT MESOTHELIOMA DRUGS BY COMPANY

3.1 Global Malignant Mesothelioma Drugs Breakdown Data by Company

3.1.1 Global Malignant Mesothelioma Drugs Annual Sales by Company (2019-2024)

3.1.2 Global Malignant Mesothelioma Drugs Sales Market Share by Company (2019-2024)

3.2 Global Malignant Mesothelioma Drugs Annual Revenue by Company (2019-2024)

3.2.1 Global Malignant Mesothelioma Drugs Revenue by Company (2019-2024)

3.2.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Company (2019-2024)

3.3 Global Malignant Mesothelioma Drugs Sale Price by Company

3.4 Key Manufacturers Malignant Mesothelioma Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Malignant Mesothelioma Drugs Product Location Distribution

3.4.2 Players Malignant Mesothelioma Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR MALIGNANT MESOTHELIOMA DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Malignant Mesothelioma Drugs Market Size by Geographic Region (2019-2024)

4.1.1 Global Malignant Mesothelioma Drugs Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Malignant Mesothelioma Drugs Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Malignant Mesothelioma Drugs Market Size by Country/Region (2019-2024)

4.2.1 Global Malignant Mesothelioma Drugs Annual Sales by Country/Region

(2019-2024)

4.2.2 Global Malignant Mesothelioma Drugs Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Malignant Mesothelioma Drugs Sales Growth

4.4 APAC Malignant Mesothelioma Drugs Sales Growth

4.5 Europe Malignant Mesothelioma Drugs Sales Growth

4.6 Middle East & Africa Malignant Mesothelioma Drugs Sales Growth

5 AMERICAS

5.1 Americas Malignant Mesothelioma Drugs Sales by Country

5.1.1 Americas Malignant Mesothelioma Drugs Sales by Country (2019-2024)

5.1.2 Americas Malignant Mesothelioma Drugs Revenue by Country (2019-2024)

5.2 Americas Malignant Mesothelioma Drugs Sales by Type

5.3 Americas Malignant Mesothelioma Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Malignant Mesothelioma Drugs Sales by Region

6.1.1 APAC Malignant Mesothelioma Drugs Sales by Region (2019-2024)

6.1.2 APAC Malignant Mesothelioma Drugs Revenue by Region (2019-2024)

6.2 APAC Malignant Mesothelioma Drugs Sales by Type

6.3 APAC Malignant Mesothelioma Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Malignant Mesothelioma Drugs by Country

7.1.1 Europe Malignant Mesothelioma Drugs Sales by Country (2019-2024)

- 7.1.2 Europe Malignant Mesothelioma Drugs Revenue by Country (2019-2024)
- 7.2 Europe Malignant Mesothelioma Drugs Sales by Type
- 7.3 Europe Malignant Mesothelioma Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Malignant Mesothelioma Drugs by Country
 - 8.1.1 Middle East & Africa Malignant Mesothelioma Drugs Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Malignant Mesothelioma Drugs Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Malignant Mesothelioma Drugs Sales by Type
- 8.3 Middle East & Africa Malignant Mesothelioma Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Malignant Mesothelioma Drugs
- 10.3 Manufacturing Process Analysis of Malignant Mesothelioma Drugs
- 10.4 Industry Chain Structure of Malignant Mesothelioma Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Malignant Mesothelioma Drugs Distributors
- 11.3 Malignant Mesothelioma Drugs Customer

12 WORLD FORECAST REVIEW FOR MALIGNANT MESOTHELIOMA DRUGS BY GEOGRAPHIC REGION

- 12.1 Global Malignant Mesothelioma Drugs Market Size Forecast by Region
 - 12.1.1 Global Malignant Mesothelioma Drugs Forecast by Region (2025-2030)
 - 12.1.2 Global Malignant Mesothelioma Drugs Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Malignant Mesothelioma Drugs Forecast by Type
- 12.7 Global Malignant Mesothelioma Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 AstraZeneca
 - 13.1.1 AstraZeneca Company Information
 - 13.1.2 AstraZeneca Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.1.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 AstraZeneca Main Business Overview
 - 13.1.5 AstraZeneca Latest Developments
- 13.2 Bristol-Myers Squibb
 - 13.2.1 Bristol-Myers Squibb Company Information
 - 13.2.2 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.2.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Bristol-Myers Squibb Main Business Overview
 - 13.2.5 Bristol-Myers Squibb Latest Developments
- 13.3 Roche

- 13.3.1 Roche Company Information
- 13.3.2 Roche Malignant Mesothelioma Drugs Product Portfolios and Specifications
- 13.3.3 Roche Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Roche Main Business Overview
- 13.3.5 Roche Latest Developments
- 13.4 Merck
 - 13.4.1 Merck Company Information
 - 13.4.2 Merck Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.4.3 Merck Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Merck Main Business Overview
 - 13.4.5 Merck Latest Developments
- 13.5 Novartis
 - 13.5.1 Novartis Company Information
 - 13.5.2 Novartis Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.5.3 Novartis Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Novartis Main Business Overview
 - 13.5.5 Novartis Latest Developments
- 13.6 Pfizer
 - 13.6.1 Pfizer Company Information
 - 13.6.2 Pfizer Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.6.3 Pfizer Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Pfizer Main Business Overview
 - 13.6.5 Pfizer Latest Developments
- 13.7 Sanofi
 - 13.7.1 Sanofi Company Information
 - 13.7.2 Sanofi Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.7.3 Sanofi Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Sanofi Main Business Overview
 - 13.7.5 Sanofi Latest Developments
- 13.8 Eli Lilly
 - 13.8.1 Eli Lilly Company Information
 - 13.8.2 Eli Lilly Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.8.4 Eli Lilly Main Business Overview
- 13.8.5 Eli Lilly Latest Developments
- 13.9 Teva Pharmaceuticals
 - 13.9.1 Teva Pharmaceuticals Company Information
 - 13.9.2 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.9.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Teva Pharmaceuticals Main Business Overview
 - 13.9.5 Teva Pharmaceuticals Latest Developments
- 13.10 Boehringer Ingelheim GmbH
 - 13.10.1 Boehringer Ingelheim GmbH Company Information
 - 13.10.2 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 Boehringer Ingelheim GmbH Main Business Overview
 - 13.10.5 Boehringer Ingelheim GmbH Latest Developments
- 13.11 Mylan
 - 13.11.1 Mylan Company Information
 - 13.11.2 Mylan Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.11.3 Mylan Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Mylan Main Business Overview
 - 13.11.5 Mylan Latest Developments
- 13.12 Fresenius Kabi
 - 13.12.1 Fresenius Kabi Company Information
 - 13.12.2 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.12.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Fresenius Kabi Main Business Overview
 - 13.12.5 Fresenius Kabi Latest Developments
- 13.13 Sun Pharmaceuticals
 - 13.13.1 Sun Pharmaceuticals Company Information
 - 13.13.2 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.13.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.13.4 Sun Pharmaceuticals Main Business Overview
- 13.13.5 Sun Pharmaceuticals Latest Developments
- 13.14 Corden Pharma
 - 13.14.1 Corden Pharma Company Information
 - 13.14.2 Corden Pharma Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.14.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.14.4 Corden Pharma Main Business Overview
 - 13.14.5 Corden Pharma Latest Developments
- 13.15 Concordia International
 - 13.15.1 Concordia International Company Information
 - 13.15.2 Concordia International Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.15.3 Concordia International Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.15.4 Concordia International Main Business Overview
 - 13.15.5 Concordia International Latest Developments
- 13.16 Kyowa Hakko Kirin
 - 13.16.1 Kyowa Hakko Kirin Company Information
 - 13.16.2 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.16.4 Kyowa Hakko Kirin Main Business Overview
 - 13.16.5 Kyowa Hakko Kirin Latest Developments
- 13.17 Polaris Pharmaceuticals
 - 13.17.1 Polaris Pharmaceuticals Company Information
 - 13.17.2 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.17.4 Polaris Pharmaceuticals Main Business Overview
 - 13.17.5 Polaris Pharmaceuticals Latest Developments
- 13.18 MolMed
 - 13.18.1 MolMed Company Information
 - 13.18.2 MolMed Malignant Mesothelioma Drugs Product Portfolios and Specifications
 - 13.18.3 MolMed Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.18.4 MolMed Main Business Overview

13.18.5 MolMed Latest Developments

13.19 Ono Pharmaceutical

13.19.1 Ono Pharmaceutical Company Information

13.19.2 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolios and Specifications

13.19.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.19.4 Ono Pharmaceutical Main Business Overview

13.19.5 Ono Pharmaceutical Latest Developments

13.20 Nichi-Iko Pharmaceutical

13.20.1 Nichi-Iko Pharmaceutical Company Information

13.20.2 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolios and Specifications

13.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.20.4 Nichi-Iko Pharmaceutical Main Business Overview

13.20.5 Nichi-Iko Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Malignant Mesothelioma Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Malignant Mesothelioma Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Pemetrexed

Table 4. Major Players of Cisplatin

Table 5. Major Players of Carboplatin

Table 6. Major Players of Gemcitabine

Table 7. Major Players of Vinorelbine

Table 8. Major Players of Others

Table 9. Global Malignant Mesothelioma Drugs Sales by Type (2019-2024) & (K Units)

Table 10. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)

Table 11. Global Malignant Mesothelioma Drugs Revenue by Type (2019-2024) & (\$ million)

Table 12. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2019-2024)

Table 13. Global Malignant Mesothelioma Drugs Sale Price by Type (2019-2024) & (USD/Unit)

Table 14. Global Malignant Mesothelioma Drugs Sales by Application (2019-2024) & (K Units)

Table 15. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2019-2024)

Table 16. Global Malignant Mesothelioma Drugs Revenue by Application (2019-2024)

Table 17. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2019-2024)

Table 18. Global Malignant Mesothelioma Drugs Sale Price by Application (2019-2024) & (USD/Unit)

Table 19. Global Malignant Mesothelioma Drugs Sales by Company (2019-2024) & (K Units)

Table 20. Global Malignant Mesothelioma Drugs Sales Market Share by Company (2019-2024)

Table 21. Global Malignant Mesothelioma Drugs Revenue by Company (2019-2024) (\$ Millions)

Table 22. Global Malignant Mesothelioma Drugs Revenue Market Share by Company

(2019-2024)

Table 23. Global Malignant Mesothelioma Drugs Sale Price by Company (2019-2024) & (USD/Unit)

Table 24. Key Manufacturers Malignant Mesothelioma Drugs Producing Area Distribution and Sales Area

Table 25. Players Malignant Mesothelioma Drugs Products Offered

Table 26. Malignant Mesothelioma Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Malignant Mesothelioma Drugs Sales by Geographic Region (2019-2024) & (K Units)

Table 30. Global Malignant Mesothelioma Drugs Sales Market Share Geographic Region (2019-2024)

Table 31. Global Malignant Mesothelioma Drugs Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 32. Global Malignant Mesothelioma Drugs Revenue Market Share by Geographic Region (2019-2024)

Table 33. Global Malignant Mesothelioma Drugs Sales by Country/Region (2019-2024) & (K Units)

Table 34. Global Malignant Mesothelioma Drugs Sales Market Share by Country/Region (2019-2024)

Table 35. Global Malignant Mesothelioma Drugs Revenue by Country/Region (2019-2024) & (\$ millions)

Table 36. Global Malignant Mesothelioma Drugs Revenue Market Share by Country/Region (2019-2024)

Table 37. Americas Malignant Mesothelioma Drugs Sales by Country (2019-2024) & (K Units)

Table 38. Americas Malignant Mesothelioma Drugs Sales Market Share by Country (2019-2024)

Table 39. Americas Malignant Mesothelioma Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 40. Americas Malignant Mesothelioma Drugs Revenue Market Share by Country (2019-2024)

Table 41. Americas Malignant Mesothelioma Drugs Sales by Type (2019-2024) & (K Units)

Table 42. Americas Malignant Mesothelioma Drugs Sales by Application (2019-2024) & (K Units)

Table 43. APAC Malignant Mesothelioma Drugs Sales by Region (2019-2024) & (K

Units)

Table 44. APAC Malignant Mesothelioma Drugs Sales Market Share by Region (2019-2024)

Table 45. APAC Malignant Mesothelioma Drugs Revenue by Region (2019-2024) & (\$ Millions)

Table 46. APAC Malignant Mesothelioma Drugs Revenue Market Share by Region (2019-2024)

Table 47. APAC Malignant Mesothelioma Drugs Sales by Type (2019-2024) & (K Units)

Table 48. APAC Malignant Mesothelioma Drugs Sales by Application (2019-2024) & (K Units)

Table 49. Europe Malignant Mesothelioma Drugs Sales by Country (2019-2024) & (K Units)

Table 50. Europe Malignant Mesothelioma Drugs Sales Market Share by Country (2019-2024)

Table 51. Europe Malignant Mesothelioma Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 52. Europe Malignant Mesothelioma Drugs Revenue Market Share by Country (2019-2024)

Table 53. Europe Malignant Mesothelioma Drugs Sales by Type (2019-2024) & (K Units)

Table 54. Europe Malignant Mesothelioma Drugs Sales by Application (2019-2024) & (K Units)

Table 55. Middle East & Africa Malignant Mesothelioma Drugs Sales by Country (2019-2024) & (K Units)

Table 56. Middle East & Africa Malignant Mesothelioma Drugs Sales Market Share by Country (2019-2024)

Table 57. Middle East & Africa Malignant Mesothelioma Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 58. Middle East & Africa Malignant Mesothelioma Drugs Revenue Market Share by Country (2019-2024)

Table 59. Middle East & Africa Malignant Mesothelioma Drugs Sales by Type (2019-2024) & (K Units)

Table 60. Middle East & Africa Malignant Mesothelioma Drugs Sales by Application (2019-2024) & (K Units)

Table 61. Key Market Drivers & Growth Opportunities of Malignant Mesothelioma Drugs

Table 62. Key Market Challenges & Risks of Malignant Mesothelioma Drugs

Table 63. Key Industry Trends of Malignant Mesothelioma Drugs

Table 64. Malignant Mesothelioma Drugs Raw Material

Table 65. Key Suppliers of Raw Materials

- Table 66. Malignant Mesothelioma Drugs Distributors List
- Table 67. Malignant Mesothelioma Drugs Customer List
- Table 68. Global Malignant Mesothelioma Drugs Sales Forecast by Region (2025-2030) & (K Units)
- Table 69. Global Malignant Mesothelioma Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 70. Americas Malignant Mesothelioma Drugs Sales Forecast by Country (2025-2030) & (K Units)
- Table 71. Americas Malignant Mesothelioma Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 72. APAC Malignant Mesothelioma Drugs Sales Forecast by Region (2025-2030) & (K Units)
- Table 73. APAC Malignant Mesothelioma Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 74. Europe Malignant Mesothelioma Drugs Sales Forecast by Country (2025-2030) & (K Units)
- Table 75. Europe Malignant Mesothelioma Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 76. Middle East & Africa Malignant Mesothelioma Drugs Sales Forecast by Country (2025-2030) & (K Units)
- Table 77. Middle East & Africa Malignant Mesothelioma Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 78. Global Malignant Mesothelioma Drugs Sales Forecast by Type (2025-2030) & (K Units)
- Table 79. Global Malignant Mesothelioma Drugs Revenue Forecast by Type (2025-2030) & (\$ Millions)
- Table 80. Global Malignant Mesothelioma Drugs Sales Forecast by Application (2025-2030) & (K Units)
- Table 81. Global Malignant Mesothelioma Drugs Revenue Forecast by Application (2025-2030) & (\$ Millions)
- Table 82. AstraZeneca Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 83. AstraZeneca Malignant Mesothelioma Drugs Product Portfolios and Specifications
- Table 84. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 85. AstraZeneca Main Business
- Table 86. AstraZeneca Latest Developments
- Table 87. Bristol-Myers Squibb Basic Information, Malignant Mesothelioma Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 88. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 89. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 90. Bristol-Myers Squibb Main Business

Table 91. Bristol-Myers Squibb Latest Developments

Table 92. Roche Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 93. Roche Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 94. Roche Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 95. Roche Main Business

Table 96. Roche Latest Developments

Table 97. Merck Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 98. Merck Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 99. Merck Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 100. Merck Main Business

Table 101. Merck Latest Developments

Table 102. Novartis Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 103. Novartis Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 104. Novartis Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 105. Novartis Main Business

Table 106. Novartis Latest Developments

Table 107. Pfizer Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 108. Pfizer Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 109. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 110. Pfizer Main Business

Table 111. Pfizer Latest Developments

Table 112. Sanofi Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 113. Sanofi Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 114. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 115. Sanofi Main Business

Table 116. Sanofi Latest Developments

Table 117. Eli Lilly Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 118. Eli Lilly Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 119. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 120. Eli Lilly Main Business

Table 121. Eli Lilly Latest Developments

Table 122. Teva Pharmaceuticals Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 123. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 124. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 125. Teva Pharmaceuticals Main Business

Table 126. Teva Pharmaceuticals Latest Developments

Table 127. Boehringer Ingelheim GmbH Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 128. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 129. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 130. Boehringer Ingelheim GmbH Main Business

Table 131. Boehringer Ingelheim GmbH Latest Developments

Table 132. Mylan Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 133. Mylan Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 134. Mylan Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 135. Mylan Main Business

Table 136. Mylan Latest Developments

Table 137. Fresenius Kabi Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 138. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 139. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$

Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 140. Fresenius Kabi Main Business

Table 141. Fresenius Kabi Latest Developments

Table 142. Sun Pharmaceuticals Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 143. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 144. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 145. Sun Pharmaceuticals Main Business

Table 146. Sun Pharmaceuticals Latest Developments

Table 147. Corden Pharma Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 148. Corden Pharma Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 149. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 150. Corden Pharma Main Business

Table 151. Corden Pharma Latest Developments

Table 152. Concordia International Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 153. Concordia International Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 154. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 155. Concordia International Main Business

Table 156. Concordia International Latest Developments

Table 157. Kyowa Hakko Kirin Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 158. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 159. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 160. Kyowa Hakko Kirin Main Business

Table 161. Kyowa Hakko Kirin Latest Developments

Table 162. Polaris Pharmaceuticals Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 163. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 164. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 165. Polaris Pharmaceuticals Main Business

Table 166. Polaris Pharmaceuticals Latest Developments

Table 167. MolMed Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 168. MolMed Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 169. MolMed Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 170. MolMed Main Business

Table 171. MolMed Latest Developments

Table 172. Ono Pharmaceutical Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 173. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 174. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 175. Ono Pharmaceutical Main Business

Table 176. Ono Pharmaceutical Latest Developments

Table 177. Nichi-Iko Pharmaceutical Basic Information, Malignant Mesothelioma Drugs Manufacturing Base, Sales Area and Its Competitors

Table 178. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolios and Specifications

Table 179. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 180. Nichi-Iko Pharmaceutical Main Business

Table 181. Nichi-Iko Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Malignant Mesothelioma Drugs
- Figure 2. Malignant Mesothelioma Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Malignant Mesothelioma Drugs Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Malignant Mesothelioma Drugs Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Malignant Mesothelioma Drugs Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of Pemetrexed
- Figure 10. Product Picture of Cisplatin
- Figure 11. Product Picture of Carboplatin
- Figure 12. Product Picture of Gemcitabine
- Figure 13. Product Picture of Vinorelbine
- Figure 14. Product Picture of Others
- Figure 15. Global Malignant Mesothelioma Drugs Sales Market Share by Type in 2023
- Figure 16. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2019-2024)
- Figure 17. Malignant Mesothelioma Drugs Consumed in Hospital Pharmacies
- Figure 18. Global Malignant Mesothelioma Drugs Market: Hospital Pharmacies (2019-2024) & (K Units)
- Figure 19. Malignant Mesothelioma Drugs Consumed in Retail Pharmacies
- Figure 20. Global Malignant Mesothelioma Drugs Market: Retail Pharmacies (2019-2024) & (K Units)
- Figure 21. Malignant Mesothelioma Drugs Consumed in Oncology Centers
- Figure 22. Global Malignant Mesothelioma Drugs Market: Oncology Centers (2019-2024) & (K Units)
- Figure 23. Malignant Mesothelioma Drugs Consumed in Others
- Figure 24. Global Malignant Mesothelioma Drugs Market: Others (2019-2024) & (K Units)
- Figure 25. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2023)
- Figure 26. Global Malignant Mesothelioma Drugs Revenue Market Share by Application

in 2023

Figure 27. Malignant Mesothelioma Drugs Sales Market by Company in 2023 (K Units)

Figure 28. Global Malignant Mesothelioma Drugs Sales Market Share by Company in 2023

Figure 29. Malignant Mesothelioma Drugs Revenue Market by Company in 2023 (\$ Million)

Figure 30. Global Malignant Mesothelioma Drugs Revenue Market Share by Company in 2023

Figure 31. Global Malignant Mesothelioma Drugs Sales Market Share by Geographic Region (2019-2024)

Figure 32. Global Malignant Mesothelioma Drugs Revenue Market Share by Geographic Region in 2023

Figure 33. Americas Malignant Mesothelioma Drugs Sales 2019-2024 (K Units)

Figure 34. Americas Malignant Mesothelioma Drugs Revenue 2019-2024 (\$ Millions)

Figure 35. APAC Malignant Mesothelioma Drugs Sales 2019-2024 (K Units)

Figure 36. APAC Malignant Mesothelioma Drugs Revenue 2019-2024 (\$ Millions)

Figure 37. Europe Malignant Mesothelioma Drugs Sales 2019-2024 (K Units)

Figure 38. Europe Malignant Mesothelioma Drugs Revenue 2019-2024 (\$ Millions)

Figure 39. Middle East & Africa Malignant Mesothelioma Drugs Sales 2019-2024 (K Units)

Figure 40. Middle East & Africa Malignant Mesothelioma Drugs Revenue 2019-2024 (\$ Millions)

Figure 41. Americas Malignant Mesothelioma Drugs Sales Market Share by Country in 2023

Figure 42. Americas Malignant Mesothelioma Drugs Revenue Market Share by Country in 2023

Figure 43. Americas Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)

Figure 44. Americas Malignant Mesothelioma Drugs Sales Market Share by Application (2019-2024)

Figure 45. United States Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 46. Canada Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 47. Mexico Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 48. Brazil Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 49. APAC Malignant Mesothelioma Drugs Sales Market Share by Region in 2023

Figure 50. APAC Malignant Mesothelioma Drugs Revenue Market Share by Regions in 2023

Figure 51. APAC Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)

Figure 52. APAC Malignant Mesothelioma Drugs Sales Market Share by Application (2019-2024)

Figure 53. China Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 54. Japan Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 55. South Korea Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 56. Southeast Asia Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 57. India Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 58. Australia Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 59. China Taiwan Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 60. Europe Malignant Mesothelioma Drugs Sales Market Share by Country in 2023

Figure 61. Europe Malignant Mesothelioma Drugs Revenue Market Share by Country in 2023

Figure 62. Europe Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)

Figure 63. Europe Malignant Mesothelioma Drugs Sales Market Share by Application (2019-2024)

Figure 64. Germany Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 65. France Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 66. UK Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 67. Italy Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Russia Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 69. Middle East & Africa Malignant Mesothelioma Drugs Sales Market Share by Country in 2023

Figure 70. Middle East & Africa Malignant Mesothelioma Drugs Revenue Market Share by Country in 2023

- Figure 71. Middle East & Africa Malignant Mesothelioma Drugs Sales Market Share by Type (2019-2024)
- Figure 72. Middle East & Africa Malignant Mesothelioma Drugs Sales Market Share by Application (2019-2024)
- Figure 73. Egypt Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 74. South Africa Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 75. Israel Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 76. Turkey Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 77. GCC Country Malignant Mesothelioma Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 78. Manufacturing Cost Structure Analysis of Malignant Mesothelioma Drugs in 2023
- Figure 79. Manufacturing Process Analysis of Malignant Mesothelioma Drugs
- Figure 80. Industry Chain Structure of Malignant Mesothelioma Drugs
- Figure 81. Channels of Distribution
- Figure 82. Global Malignant Mesothelioma Drugs Sales Market Forecast by Region (2025-2030)
- Figure 83. Global Malignant Mesothelioma Drugs Revenue Market Share Forecast by Region (2025-2030)
- Figure 84. Global Malignant Mesothelioma Drugs Sales Market Share Forecast by Type (2025-2030)
- Figure 85. Global Malignant Mesothelioma Drugs Revenue Market Share Forecast by Type (2025-2030)
- Figure 86. Global Malignant Mesothelioma Drugs Sales Market Share Forecast by Application (2025-2030)
- Figure 87. Global Malignant Mesothelioma Drugs Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Malignant Mesothelioma Drugs Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G44BC089151FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G44BC089151FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970